Since the early 1960s, Ares-Serono has been a leader in developing the most effective and convenient drug therapies to treat infertility and offers a full range of pharmaceutical products in this therapeutic area. Committed to improving the quality of care in reproductive health, Ares-Serono is also developing a complete portfolio of recombinant fertility hormones. Fertinex represents another major advance in the development of ethical pharmaceuticals to treat couples with infertility. In addition, the high specific activity and purity of Fertinex offers the reproductive specialist a new benchmark for drug therapies. Infertility is commonly defined as the inability to conceive or carry a pregnancy to term, and may be the result of various medical conditions.
Infertility affects both the male and female partners equally.
Serono Laboratories, Inc. , headquartered in Norwell, MA, is a member company of The Ares-Serono Group , the world's foremost developer and manufacturer of pharmaceuticals for the treatment of infertility. Each ampule of Fertinex contains either 75 IU or 150 IU of highly purified FSH and 10 mg lactose in a sterile, lyophilized form. M sodium hydroxide. Fertinex is administered by subcutaneous injection. FSH, the active component of Fertinex , is the primary hormone responsible for follicular recruitment and development.